Compositions and methods for diabetes treatment
OwnerJoseph S. Takahashi, Steve A. Kayinventors
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods and compositions for the treatment or prevention of type 2 diabetes by administering an effective amount of a melatonin receptor agonist to a human subject in need of such treatment or prevention.
Claims38
A method for the treatment of type 2 diabetes in a human subject in need thereof, comprising administering to the subject an effective amount of a melatonin receptor (MTR) agonist about 6-12 hours before a meal.
A pharmaceutical composition comprising a melatonin receptor (MTR) agonist), wherein the composition is formulated as a controlled release formulation to provide for the sustained release of the MTR agonist.
A pharmaceutical composition comprising a melatonin receptor (MTR) agonist and one or more additional therapeutic agents for the treatment of diabetes, wherein the composition is formulated as a controlled release formulation to provide for the immediate release of the MTR agonist and the delayed release of the one or more additional therapeutic agents.
A pharmaceutical composition comprising a melatonin receptor (MTR) agonist and one or more additional therapeutic agents for the treatment of diabetes, wherein the composition is formulated as a controlled release formulation to provide for the sustained release of the MTR agonist and the immediate release of the one or more additional therapeutic agents.
A pharmaceutical composition comprising a melatonin receptor (MTR) agonist and one or more additional therapeutic agents for the treatment of diabetes, wherein the composition is formulated as a controlled release formulation to provide for the sustained release of the MTR agonist and the delayed release of the one or more additional therapeutic agents.
Dependencies are inferred from the claim text.